ADVERTISEMENT

ADA 2021 — T2D: weekly efpeglenatide significantly reduces risk for cardiovascular events

Pavankumar Kamat   |   Conference Report   |   30 June 2021
ADVERTISEMENT

Takeaway

  • A weekly injection of 4 or 6 mg efpeglenatide was associated with a lower risk for cardiovascular events than placebo in patients with type 2 diabetes (T2D) and either a history of cardiovascular (CV) disease or current kidney disease plus at least 1 additional CV risk factor.

Why this matters...

          

March Challenge

Ends in 4d 2h
left
right

Topic Challenges

left
right